SEC Company Response from ACADIA PHARMACEUTICALS INC (ACAD) (CIK 0001070494) (ACAD) — Sep 19, 2008
ACADIA PHARMACEUTICALS INC (ACAD) (CIK 0001070494)
Date: Sept. 19, 2008 · CIK: 0001070494 · Accession: 0001193125-08-198520
AI Filing Summary & Sentiment
File numbers found in text: 333-153347
Referenced dates: September 15, 2008
Letter
United States Securities and Exchange Commission Sebastian Gomez Abero RE: ACADIA Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-153347) Amendment No. 1
Dear Messrs. Riedler and Abero:
We are writing in response to your letter dated September 15, 2008 (the “Comment Letter”) with respect to a Registration Statement on Form S-3, File No. 333-153347 (the “Registration Statement”), originally filed by ACADIA Pharmaceuticals Inc. (the “Company”) on September 5, 2008. Enclosed for electronic filing via EDGAR pursuant to the Securities Act of 1933, as amended, on behalf of the Company, is Amendment No. 1 (“Amendment No. 1”) to the Registration Statement. The copy of Amendment No. 1 that is enclosed with the paper copy of this letter is marked to show changes from the Registration Statement as originally filed with the Securities and Exchange Commission (the “Commission”). Amendment No. 1 is being filed in response to a comment received from the staff of the Commission (the “Staff”) as set forth in the Comment Letter. For convenience, the text of the comment has been incorporated into this letter in addition to the Company’s response below.
Staff Comment and Company Response
General
We note that the registration statement relates to 7,422,364 shares of common stock that may be sold by either the selling stockholder or the registrant. The registration statement may not register shares to be sold by the selling stockholder or, in the alternative, by the registrant. Instead, the registration statement must separately identify the shares to be sold by the selling stockholder and the shares to be sold by the registrant. Please revise your registration statement accordingly.
Response: The Company acknowledges the Staff’s comment and has revised the Registration Statement through Amendment No. 1 such that all 7,422,364 shares of the Company’s Common Stock registered thereunder are identified as shares to be sold by the selling stockholder. All references to the Company’s ability to alternatively sell such shares under the Registration Statement have been removed.
4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM
SEC
September 19, 2008
Page Two
The Company respectfully requests the Staff’s assistance in completing the review of the Registration Statement and Amendment No. 1 as soon as possible. Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding Amendment No. 1 or this response letter to me at (858) 550-6012 or to Sean Clayton at (858) 550-6034.
Sincerely,
/s/ D. Bradley Peck
Show Raw Text
CORRESP 1 filename1.htm SEC Response Letter D. Bradley Peck (858) 550-6012 bpeck@cooley.com September 19, 2008 United States Securities and Exchange Commission Mail Stop 6010 100 F Street N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Sebastian Gomez Abero RE: ACADIA Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-153347) Amendment No. 1 Dear Messrs. Riedler and Abero: We are writing in response to your letter dated September 15, 2008 (the “Comment Letter”) with respect to a Registration Statement on Form S-3, File No. 333-153347 (the “Registration Statement”), originally filed by ACADIA Pharmaceuticals Inc. (the “Company”) on September 5, 2008. Enclosed for electronic filing via EDGAR pursuant to the Securities Act of 1933, as amended, on behalf of the Company, is Amendment No. 1 (“Amendment No. 1”) to the Registration Statement. The copy of Amendment No. 1 that is enclosed with the paper copy of this letter is marked to show changes from the Registration Statement as originally filed with the Securities and Exchange Commission (the “Commission”). Amendment No. 1 is being filed in response to a comment received from the staff of the Commission (the “Staff”) as set forth in the Comment Letter. For convenience, the text of the comment has been incorporated into this letter in addition to the Company’s response below. Staff Comment and Company Response General We note that the registration statement relates to 7,422,364 shares of common stock that may be sold by either the selling stockholder or the registrant. The registration statement may not register shares to be sold by the selling stockholder or, in the alternative, by the registrant. Instead, the registration statement must separately identify the shares to be sold by the selling stockholder and the shares to be sold by the registrant. Please revise your registration statement accordingly. Response: The Company acknowledges the Staff’s comment and has revised the Registration Statement through Amendment No. 1 such that all 7,422,364 shares of the Company’s Common Stock registered thereunder are identified as shares to be sold by the selling stockholder. All references to the Company’s ability to alternatively sell such shares under the Registration Statement have been removed. 4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM SEC September 19, 2008 Page Two The Company respectfully requests the Staff’s assistance in completing the review of the Registration Statement and Amendment No. 1 as soon as possible. Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding Amendment No. 1 or this response letter to me at (858) 550-6012 or to Sean Clayton at (858) 550-6034. Sincerely, /s/ D. Bradley Peck D. Bradley Peck cc: Glenn F. Baity, ACADIA Pharmaceuticals Inc. J. Patrick Loofbourrow, Cooley Godward Kronish LLP Sean M. Clayton, Cooley Godward Kronish LLP 4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM